Objective     To study the effect of resveratrol (RES) on pulmonary virus titer and airway inflammation in mice infected with respiratory syncytial virus (RSV).      Methods     Twenty-four female BALB/c mice at the age of 6-8 weeks

treated with intra-abdominal cyclophosphamide (CYP) at the dose of 100 mg/kg

were randomly divided into control group

RSV infection group

and RES treatment group (8 in each group). Five days after CYP treatment

a RES infection model was induced by intranasal drip of RES. One hour after RES infection

the mice received intraperitoneal injection of RES or inhaled it at the dose of 30mg/(kg·d). Five days later

airway hyper-response (AHR) in lucid mice was detected. The mice were then killed to detect the pulmonary RSV titers in the lung

the number of cells in bronchoalevolar lavage fluid (BALF)

inflammation in lung tissue and its score.      Results     The pulmonary RSV titer

the number of cells in BALF

the score of inflammation in lung tissue

and the airway AHR were significantly lower in RES treatment group than in RSV infection group (P0.01). However

no significant difference was observed between RES treatment group and control group.      Conclusion     Differenly administrated RES can relieve RSV-induced inflammation and AHR by reducing pulmonary titer and inhibiting RSV replication in vivo.